Most Read Articles
Prof Winnie Yeo, 13 Aug 2020
Despite the availability of antiemetics, a substantial proportion of patients receiving chemotherapy experience chemotherapy-induced nausea and vomiting (CINV), significantly impacting treatment compliance and quality of life (QoL). At the 24th Annual Scientific Symposium of the Hong Kong Cancer Institute, Professor Winnie Yeo of the Department of Clinical Oncology, Chinese University of Hong Kong, presented results of a local study showing superior efficacy of the fixed-dose netupitant/palonosetron (NEPA) combination regimen vs aprepitant-based regimen in controlling CINV in breast cancer patients receiving highly emetogenic anthracycline-cyclophosphamide (AC) chemotherapy.
Prof. Charlie Gourley, 30 Sep 2020

First-line poly(ADP-ribose)polymerase (PARP) inhibitor maintenance therapy significantly increases progression-free survival (PFS) in high-grade ovarian cancer patients. However, questions remain regarding the ability of PARP inhibitors to increase the cure rate, the types of patients most likely to benefit from them, and when it is best to employ them. In a virtual small-group meeting with experts in Hong Kong, Professor Charlie Gourley of the University of Edinburgh, Edinburgh, UK discussed the criteria for optimal patient selection and the positioning of PARP inhibitors in the patient journey.

Dr. Kathleen Moore, 30 Sep 2020
Most patients with advanced ovarian cancer (OC) relapse after standard cytoreductive surgery and platinum-based chemotherapy. At a webcast organized by the Hong Kong Society of Clinical Oncology, Dr Kathleen Moore of the University of Oklahoma in Norman, Oklahoma, US, discussed the results of the SOLO-1 trial, which demonstrated significant progression-free survival (PFS) benefits associated with maintenance therapy using the poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitor, olaparib, in patients with newly diagnosed, advanced BRCA-mutated OC who had complete or partial response (CR/PR) to first-line platinum-based chemotherapy. 
Dr. Thomas Chan, 05 Oct 2020
Current international guidelines on management of chronic lymphocytic leukaemia (CLL) recommend the use of B cell lymphoma-2 (BCL-2) inhibitors, such as venetoclax, in patients with relapsed or refractory (R/R) disease with or without chromosome 17p deletion, based on improvements in progression-free survival (PFS) and overall survival (OS) and a high rate of undetectable minimal residual disease (uMRD). Dr Thomas Chan, Specialist in Haematology & Haematological Oncology in Hong Kong, discussed these recent advances in R/R CLL management with MIMS Oncology.

One-stop screening of CRC, breast and prostate cancer shows promising early results

Christina Lau
6 days ago
From left: Prof Simon Ng, Dr Polly Cheung, a patient diagnosed with early breast cancer through the programme, Prof Joseph Sung, Mr Leong Cheung, Prof Samuel Wong, Prof Anthony Ng

A programme that offers one-stop screening of colorectal cancer (CRC), breast cancer and prostate cancer is effective with a high level of acceptance among asymptomatic individuals in Hong Kong, researchers from the Chinese University of Hong Kong (CUHK) have reported.

The CUHK Jockey Club Multi-Cancer Prevention Programme, a 5-year programme launched in 2018, aims to provide free cancer screening to asymptomatic Hong Kong residents aged 40–75 years, and to raise public awareness about screening of obesity-related cancers.

With a target recruitment of 10,000, a total of 3,446 individuals (male, 44.7 percent; overweight or obese, 87.6 percent) had been enrolled into the programme between 6 August 2018 and 18 August 2020.

Among 3,230 participants eligible for faecal occult blood test, 367 (11.4 percent) had a positive result and were offered colonoscopy. As of 18 August 2020, colonoscopy results were available for 347 of the participants, of whom 151 (43.5 percent) were found to have 1–3 adenomas, while 95 (27.4 percent) had advanced adenoma and 10 (2.9 percent; 0.3 percent of those eligible for faecal occult blood test) had CRC.

Most participants (n=3,146) were also eligible for breast (n=1,717) or prostate (n=1,429) cancer screening. A majority of these individuals (1,703 women and all men) were willing to undergo breast or prostate cancer screening following CRC screening.

Including those who were not eligible for CRC screening, a total of 1,846 female participants and 1,516 male participants were eligible for screening mammography and evaluation of prostate-specific antigen (PSA) level with or without Prostate Health Index (PHI), respectively.

Among 1,828 female participants with mammography reports available, 45 (2.4 percent) had a positive result (ie, Breast Imaging Reporting and Data System [BI-RADS] 4 or 5) and were offered breast ultrasound as well as biopsy. Breast cancer was diagnosed on biopsy in 15 women (0.8 percent of those eligible for mammography).

Of the 1,516 male participants who underwent prostate cancer screening, 98 were offered prostate ultrasound and biopsy. Prostate cancer was diagnosed on biopsy in 37 men (2.4 percent of those eligible for PSA test).

Screening for metabolic syndrome was also offered to the participants, with 50 new cases of diabetes diagnosed through the programme. These diabetes patients were referred for further management, while overweight or obese participants were given classes on exercise and diet to facilitate weight management and reduce cancer risk.

According to the researchers, these results demonstrate the feasibility and effectiveness of one-stop screening for CRC, breast cancer and prostate cancer among asymptomatic individuals.

Overweight or obesity is associated with an increased risk of CRC, breast cancer and prostate cancer. [Gut 2014;63:1130-1136; Obesity Reviews 2003;4:157-173; Recent Results Cancer Res 2016;208:137-153]

“The programme aims to raise awareness of colorectal health and overweight or obesity among Hong Kong residents aged 40–75 years. Recruitment has been ongoing,” said Professor Joseph Sung, programme director and Mok Hing Yiu Professor of Medicine, CUHK.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Hong Kong digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Prof Winnie Yeo, 13 Aug 2020
Despite the availability of antiemetics, a substantial proportion of patients receiving chemotherapy experience chemotherapy-induced nausea and vomiting (CINV), significantly impacting treatment compliance and quality of life (QoL). At the 24th Annual Scientific Symposium of the Hong Kong Cancer Institute, Professor Winnie Yeo of the Department of Clinical Oncology, Chinese University of Hong Kong, presented results of a local study showing superior efficacy of the fixed-dose netupitant/palonosetron (NEPA) combination regimen vs aprepitant-based regimen in controlling CINV in breast cancer patients receiving highly emetogenic anthracycline-cyclophosphamide (AC) chemotherapy.
Prof. Charlie Gourley, 30 Sep 2020

First-line poly(ADP-ribose)polymerase (PARP) inhibitor maintenance therapy significantly increases progression-free survival (PFS) in high-grade ovarian cancer patients. However, questions remain regarding the ability of PARP inhibitors to increase the cure rate, the types of patients most likely to benefit from them, and when it is best to employ them. In a virtual small-group meeting with experts in Hong Kong, Professor Charlie Gourley of the University of Edinburgh, Edinburgh, UK discussed the criteria for optimal patient selection and the positioning of PARP inhibitors in the patient journey.

Dr. Kathleen Moore, 30 Sep 2020
Most patients with advanced ovarian cancer (OC) relapse after standard cytoreductive surgery and platinum-based chemotherapy. At a webcast organized by the Hong Kong Society of Clinical Oncology, Dr Kathleen Moore of the University of Oklahoma in Norman, Oklahoma, US, discussed the results of the SOLO-1 trial, which demonstrated significant progression-free survival (PFS) benefits associated with maintenance therapy using the poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitor, olaparib, in patients with newly diagnosed, advanced BRCA-mutated OC who had complete or partial response (CR/PR) to first-line platinum-based chemotherapy. 
Dr. Thomas Chan, 05 Oct 2020
Current international guidelines on management of chronic lymphocytic leukaemia (CLL) recommend the use of B cell lymphoma-2 (BCL-2) inhibitors, such as venetoclax, in patients with relapsed or refractory (R/R) disease with or without chromosome 17p deletion, based on improvements in progression-free survival (PFS) and overall survival (OS) and a high rate of undetectable minimal residual disease (uMRD). Dr Thomas Chan, Specialist in Haematology & Haematological Oncology in Hong Kong, discussed these recent advances in R/R CLL management with MIMS Oncology.